Koneksa Health

Executive Summary

Koneksa Health is a pioneering digital health company that accelerates drug development by seamlessly integrating digital biomarkers, wearable sensors, and traditional clinical data. Founded in 2014 and headquartered in New York, the company's proprietary platform enables remote, patient-centric data collection combined with advanced analytics, generating deeper insights for clinical trials and real-world evidence. By digitizing endpoints and leveraging real-time monitoring, Koneksa helps pharmaceutical sponsors reduce trial costs, shorten timelines, and enhance data quality. The company offers end-to-end services, from trial design through regulatory-grade digital endpoint validation, positioning itself as a critical partner in the shift toward decentralized and data-driven clinical research. Koneksa Health's value proposition is particularly compelling in therapeutic areas where continuous, objective measurements—such as motion, sleep, or respiratory parameters—can replace subjective patient reports or infrequent clinic visits. With the FDA increasingly accepting digital endpoints, and the broader industry embracing remote monitoring, Koneksa is poised for growth. Its platform not only supports late-stage clinical trials but also enables evidence generation for commercial products. As a private company, Koneksa likely relies on partnerships and funding rounds to scale. Given its established presence and relevance in the digital health landscape, the company is well-positioned to capitalize on the growing demand for decentralized trial solutions and regulatory-grade digital biomarkers.

Upcoming Catalysts (preview)

• Q3 2026Major pharma partnership for a therapeutic area (e.g., neurology or respiratory)70% success
• Q4 2026FDA acceptance of a digital endpoint for a pivotal clinical trial60% success
• Q2 2026Series C funding round to scale platform and commercialize80% success